Therapeutic agents for the prevention of primary graft dysfunction after lung transplantation : a comprehensive narrative review
Poupard, Andréa M Mullin, Georgie
Poupard, Andréa M
Mullin, Georgie
Affiliation
University Hospitals Birmingham NHS Foundation Trust; Walsall Healthcare NHS Trust
Other Contributors
Publication date
2026-01-06
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Primary graft dysfunction (PGD) remains the leading cause of morbidity and mortality following lung transplantation. This narrative review explores current evidence regarding pharmacological strategies for the prevention and management of PGD. A comprehensive literature search identified randomized controlled trials and clinical studies evaluating therapeutic agents targeting ischemia-reperfusion injury and inflammatory pathways. Interventions assessed include inhaled nitric oxide, surfactants, complement inhibitors, platelet-activating factor antagonists, and novel anti-inflammatory agents. Despite promising preclinical data, most trials failed to demonstrate statistically significant improvements in clinical outcomes, primarily due to small sample sizes and methodological heterogeneity. Current PGD management remains supportive and modeled on acute respiratory distress syndrome (ARDS) principles. Future research should focus on multicenter, adequately powered studies testing multimodal strategies combining pharmacologic and procedural interventions. Preventing PGD will be essential to improving early survival and long-term graft function in lung transplant recipients.
Citation
Poupard AM, Mullin G. Therapeutic agents for the prevention of primary graft dysfunction after lung transplantation: A comprehensive narrative review. Transplant Rev (Orlando). 2026 Jan 6;40(2):101000. doi: 10.1016/j.trre.2026.101000. Epub ahead of print. PMID: 41506197.
Type
Article